Sickle cell anemia: Pathophysiology, management, and prospects for the future
- 1 January 1991
- journal article
- review article
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 6 (4) , 221-223
- https://doi.org/10.1002/jca.2920060410
Abstract
Sickle cell anemia is present in about 1 in 600 Black Americans at birth. It claims the life of many infants, causes pain and suffering in adults, and usually culminates in premature death. We currently understand a great deal about this disease on a molecular, cellular, and clinical basis. The results of years of research are slowly being translated to innovative therapies and improvements in patient care. In this paper I review the pathophysiology of this disorder, highlight the currently available treatment, and discuss new forms of therapy that promise a more direct approach to avoiding the many complications of sickle cell anemia.Keywords
This publication has 12 references indexed in Scilit:
- Alloimmunization in Sickle Cell Anemia and Transfusion of Racially Unmatched BloodNew England Journal of Medicine, 1990
- Hematologic Responses of Patients with Sickle Cell Disease to Treatment with HydroxyureaNew England Journal of Medicine, 1990
- Effect of hydroxyurea on the rheological properties of sickle erythrocytes in vivoAmerican Journal of Hematology, 1989
- Prophylactic Red-Cell Transfusions in Pregnant Patients with Sickle Cell DiseaseNew England Journal of Medicine, 1988
- BONE MARROW TRANSPLANTATION IN FIVE CHILDREN WITH SICKLE CELL ANAEMIAThe Lancet, 1988
- Levels of Fetal Hemoglobin Necessary for Treatment of Sickle Cell DiseaseNew England Journal of Medicine, 1988
- Prophylaxis with Oral Penicillin in Children with Sickle Cell AnemiaNew England Journal of Medicine, 1986
- Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia.Journal of Clinical Investigation, 1984
- 5-Azacytidine stimulates fetal hemoglobin synthesis in anemic baboons.Proceedings of the National Academy of Sciences, 1982
- Methylation and gene controlNature, 1982